Editorial: Anemia Management with Erythropoiesis-Stimulating Agents: A Risk–Benefit Update

Matti S. Aapro
The Oncologist 2008; 13(Supplement 3): 1-3; doi:10.1634/theoncologist.13-S3-1
[Full Text] [PDF]  

Safety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications

Pere Gascón
The Oncologist 2008; 13(Supplement 3): 4-10; doi:10.1634/theoncologist.13-S3-4
[Abstract] [Full Text] [PDF]  

Venous Thromboembolic Events and Erythropoiesis-Stimulating Agents: An Update

Mario Dicato
The Oncologist 2008; 13(Supplement 3): 11-15; doi:10.1634/theoncologist.13-S3-11
[Abstract] [Full Text] [PDF]  

Erythropoietin Receptors on Tumor Cells: What Do They Mean?

Joachim Fandrey
The Oncologist 2008; 13(Supplement 3): 16-20; doi:10.1634/theoncologist.13-S3-16
[Abstract] [Full Text] [PDF]  

Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis

Peter Vaupel
The Oncologist 2008; 13(Supplement 3): 21-26; doi:10.1634/theoncologist.13-S3-21
[Abstract] [Full Text] [PDF]  

Treatment Options for Anemia, Taking Risks into Consideration: Erythropoiesis-Stimulating Agents Versus Transfusions

Jean-Philippe Spano, David Khayat
The Oncologist 2008; 13(Supplement 3): 27-32; doi:10.1634/theoncologist.13-S3-27
[Abstract] [Full Text] [PDF]  

September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents

Matti S. Aapro, Hartmut Link
The Oncologist 2008; 13(Supplement 3): 33-36; doi:10.1634/theoncologist.13-S3-33
[Abstract] [Full Text] [PDF]  

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.